Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CETIRIZINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE ALLERGY versus CETIRIZINE HYDROCHLORIDE ALLERGY.
AZELASTINE HYDROCHLORIDE ALLERGY vs CETIRIZINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine with mast cell stabilizing properties; selectively antagonizes histamine H1 receptors, reducing nasal pruritus, sneezing, rhinorrhea, and ocular symptoms.
Cetirizine hydrochloride is a second-generation histamine H1-receptor antagonist. It acts by selectively and reversibly blocking histamine H1 receptors on effector cells (e.g., smooth muscle, endothelial cells, mucous glands), thereby inhibiting histamine-mediated allergic responses such as vasodilation, increased vascular permeability, bronchoconstriction, and itching. It does not prevent histamine release but antagonizes its effects.
One spray (137 mcg) per nostril twice daily (total 548 mcg/day). Intranasal route.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 22 hours (range 16-26 hours) at steady state, supporting twice-daily dosing. The half-life may be prolonged in elderly patients or those with hepatic impairment.
Terminal elimination half-life: approximately 8-11 hours in healthy adults; increases to ~18-20 hours in elderly (due to decreased renal function); prolonged in renal impairment (CrCl <31 mL/min: up to 20-30 hours)
Azelastine is primarily eliminated via renal excretion (approximately 75% as metabolites, <10% unchanged) and fecal excretion (approximately 25%) after oral administration. Biliary excretion is minimal.
Renal: approximately 70% (60% as unchanged drug, 10% as metabolites); Fecal: approximately 10%; Biliary: negligible
Category C
Category A/B
Antihistamine
Antihistamine